Want to see AU:RGT full AI Analyst Report?
RGT Stock Chart & Stats
AU$0.08
>-AU$0.01(-2.00%)
At close: 4:00 PM EST
AU$0.08
>-AU$0.01(-2.00%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.32
Previous CloseN/A
Volume362.25K
Average Volume (3M)77.74K
Market Cap
AU$6.41M
Enterprise ValueAU$10.41M
Total Cash (Recent Filing)AU$1.53M
Total Debt (Recent Filing)AU$8.91M
Price to Earnings (P/E)―
Beta-1.15
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding116,609,580
10 Day Avg. Volume131,422
30 Day Avg. Volume77,736
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.54
Price to Sales (P/S)7.94
P/FCF Ratio-0.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Niche Specialty / Cannabinoid FocusA focused specialty and cannabinoid therapeutics strategy creates durable barriers to entry via regulatory complexity, formulation expertise and niche channel relationships. These structural attributes can support differentiated pricing and defensible market positions if development and approvals progress.
Lean Operating StructureA very small headcount implies low fixed overhead and operational flexibility, enabling the company to extend runway through outsourcing and partnerships. For a development-stage specialist, this structural lean footprint reduces cash drain and preserves capital for core R&D or regulatory milestones.
Material Gross Margin Improvement In 2025An uptick in gross margin signals potential product mix or cost-of-goods improvements that are durable if sustained. Higher gross margin creates room to absorb R&D and SG&A, improving the path to scalable profitability once revenue growth resumes or fixed costs are controlled.
Bears Say
Negative Stockholders' EquitySustained negative equity is a fundamental balance-sheet weakness that limits financial flexibility, may restrict access to secured financing, and increases the risk of covenant breaches or insolvency in stress scenarios. It structurally weakens the company’s ability to fund growth internally.
Persistent Heavy Free Cash Flow BurnOngoing, large negative free cash flow requires continual external financing, increasing dilution risk and dependency on capital markets. This chronic cash burn limits ability to self-fund development, delays scaling initiatives, and raises long-term solvency concerns absent structural cash improvement.
Steep Revenue Decline And Operating LossesA sharp, multi-year revenue contraction alongside persistent operating losses indicates weakening commercial traction and impaired scale economics. Recovering sustainable revenue growth will likely require new approvals, product launches, or strategy shifts, making near-term profitability structurally challenging.
Argent Biopharma News
RGT FAQ
What was Argent Biopharma’s price range in the past 12 months?
Argent Biopharma lowest share price was AU$0.03 and its highest was AU$0.32 in the past 12 months.
What is Argent Biopharma’s market cap?
Argent Biopharma’s market cap is AU$6.41M.
When is Argent Biopharma’s upcoming earnings report date?
Argent Biopharma’s upcoming earnings report date is Aug 28, 2026 which is in 37 days.
How were Argent Biopharma’s earnings last quarter?
Argent Biopharma released its earnings results on Feb 27, 2026. The company reported -AU$0.038 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.038.
Is Argent Biopharma overvalued?
According to Wall Street analysts Argent Biopharma’s price is currently Overvalued.
Does Argent Biopharma pay dividends?
Argent Biopharma does not currently pay dividends.
What is Argent Biopharma’s EPS estimate?
Argent Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Argent Biopharma have?
Argent Biopharma has 116,609,580 shares outstanding.
What happened to Argent Biopharma’s price movement after its last earnings report?
Argent Biopharma reported an EPS of -AU$0.038 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Argent Biopharma?
Currently, no hedge funds are holding shares in AU:RGT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Argent Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.17%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-29.21%
Trailing 12-Months
Company Description
Argent Biopharma
Argent BioPharma Limited, an Australian-headquartered biopharmaceutical firm founded in 2014, operates as a clinical-stage entity focused on developing innovative nano-engineered therapeutics. The company's core mission involves crafting treatments designed to re-establish a healthy balance between the nervous and immune systems, with its reach extending internationally to locations including Malta and Slovenia. Its diverse pipeline of product candidates is progressing through various clinical phases. CimetrA, a leading contender, is currently in Phase III trials targeting acute lung injury and Acute Respiratory Distress Syndrome (ARDS). For refractory epilepsy, CannEpil is undergoing Phase I clinical evaluation. Additionally, CogniCann is advancing through Phase IIA trials, aiming to offer symptomatic relief for Dementia and Alzheimer's disease. Beyond these clinical programs, Argent BioPharma is actively involved in the preclinical development of Irnican for Glioblastoma Multiforme and dedicates research and development efforts to wound treatment. The company has also forged a strategic partnership with SINTEF to enhance antimicrobial solutions for chronic wounds and explore potential applications in oncologic wound care. Previously known as MGC Pharmaceuticals Limited, the company officially rebranded to Argent BioPharma Limited.
Technical Analysis
Elixinol Wellness
―
Cann Group
―
Little Green Pharma Ltd.
―
Althea Group Holdings Ltd.
―
Cronos Australia Ltd.
―